Anil Gupta has been appointed as the Senior Vice President, and Sanjay Singhania has taken charge as the Vice President of PHDCCI
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Miels will formally assume the role on January 1, 2026
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Maria Soler Nunez appointed as Chief Quality Officer
He has been associated with the Zydus Group since 2009
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Subscribe To Our Newsletter & Stay Updated
